Department of Cardiology, Academic Medical Center–University of Amsterdam, Amsterdam, the Netherlands.
J Am Coll Cardiol. 2011 Jan 4;57(1):29-36. doi: 10.1016/j.jacc.2010.06.053.
We investigated whether multiple biomarkers improve prognostication in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention.
Few data exist on the prognostic value of combined biomarkers.
We used data from 1,034 STEMI patients undergoing primary percutaneous coronary intervention in a high-volume percutaneous coronary intervention center in the Netherlands and investigated whether combining N-terminal pro-brain natriuretic peptide, glucose, C-reactive protein, estimated glomerular filtration rate, and cardiac troponin T improved the prediction of mortality. A risk score was developed based on the strongest predicting biomarkers in multivariate Cox regression. The additional prognostic value of the strongest predicting biomarkers to the established prognostic factors (age, body weight, diabetes, hypertension, systolic blood pressure, heart rate, anterior myocardial infarction, and time to treatment) was assessed in multivariable Cox regression.
During follow-up (median, 901 days), 120 of the 1,034 patients died. In Cox regression, glucose, estimated glomerular filtration rate, and N-terminal pro-brain natriuretic peptide were the strongest predictors for mortality (p < 0.05, for all). A risk score incorporating these biomarkers identified a high-risk STEMI subgroup with a significantly higher mortality when compared with an intermediate- or low-risk subgroup (p < 0.001). Addition of the 3 biomarkers to established prognostic factors significantly improved prediction for mortality, as shown by the net reclassification improvement (0.481, p < 0.001) [corrected] and integrated discrimination improvement (0.0226, p = 0.03) [corrected].
Our data suggest that addition of a multimarker to a model including established risk factors improves the prediction of mortality in STEMI patients undergoing primary percutaneous coronary intervention. Furthermore, the use of a simple risk score based on these biomarkers identifies a high-risk subgroup.
本研究旨在探讨在接受直接经皮冠状动脉介入治疗(PPCI)的 ST 段抬高型心肌梗死(STEMI)患者中,多种生物标志物是否能改善预后。
目前关于联合生物标志物预后价值的数据较少。
本研究纳入了在荷兰一家大容量经皮冠状动脉介入治疗中心接受 PPCI 的 1034 例 STEMI 患者的数据,旨在探讨联合检测 N 末端脑钠肽前体(NT-proBNP)、血糖、C 反应蛋白、估算肾小球滤过率和心脏肌钙蛋白 T 是否能提高死亡率的预测能力。使用多变量 Cox 回归分析确定基于最强预测生物标志物的风险评分。采用多变量 Cox 回归分析评估最强预测生物标志物对既定预后因素(年龄、体重、糖尿病、高血压、收缩压、心率、前壁心肌梗死和治疗时间)的额外预后价值。
在随访期间(中位数为 901 天),1034 例患者中有 120 例死亡。在 Cox 回归中,血糖、估算肾小球滤过率和 NT-proBNP 是死亡率的最强预测因子(p<0.05,均)。纳入这些生物标志物的风险评分可识别出高危 STEMI 亚组,与中危或低危亚组相比,死亡率显著升高(p<0.001)。与既定预后因素相比,将 3 种生物标志物加入后,对死亡率的预测能力显著提高,表现为净重新分类改善(0.481,p<0.001)[校正]和综合判别改善(0.0226,p=0.03)[校正]。
我们的数据表明,在包括既定危险因素的模型中加入多标志物可改善接受直接 PPCI 的 STEMI 患者的死亡率预测。此外,基于这些生物标志物的简单风险评分可识别出高危亚组。